# Neogene Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neogene-therapeutics

- Industry: Biotechnology
- Headquarters: Amsterdam, Netherlands
- Website: www.neogene.com
- Total disclosed funding: $110M
- Latest round: Series A (Sep 14, 2020)
- Investors on record: 8

## About

Neogene Therapeutics, Inc. specializes in developing innovative cell therapies targeting cancer treatment, harnessing the power of T-cell technology for transformative patient outcomes.Founded in 2018 and headquartered in Amsterdam, Netherlands, Neogene Therapeutics, Inc. focuses on creating curative cell therapies for oncology. The company was established by Carsten Linnemann, who has a background in immunotherapy. Neogene has completed a total of 3 deals, with the latest round being a TRADE SALE on November 29, 2022, where AstraZeneca acquired the company for USD 200.00 mn, totaling the amount raised to USD 200.00 mn.Neogene Therapeutics, Inc. is dedicated to the development of innovative cell therapies designed specifically for cancer treatment. The company’s products leverage advanced T-cell technologies that focus on enhancing the immune system's ability to target and eliminate cancer cells, aiming to address significant unmet needs in oncology.Neogene Therapeutics, Inc. generates revenue primarily through partnerships, collaborations, and the sale of its therapeutic products. The company's financial model is structured around agreements that facilitate the development and commercialization of its therapies, ensuring sustainability and growth within the biopharmaceutical marketplace.The acquisition by AstraZeneca is set to accelerate the development of potentially curative cell therapies. Neogene Therapeutics plans to further enhance its product pipeline and expand into new markets, with significant focus on global regions that are currently underserved in oncology. The additional funding from the recent TRADE SALE of USD 200.00 mn, inclusive of potential contingent considerations, will support these initiatives and foster innovation in cancer treatment.

## Funding rounds

- Series A, Sep 14, 2020, $110M — TPG, Polaris Partners, Pontifax Venture Capital, Syncona, EcoR1 Capital, Vida Ventures, Two River, Jeito Capital

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A
- Two River (https://capitalatlas.ai/funds/two-river) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A